Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company focused on areas of hematologic malignancies, solid tumors and rare genetic diseases. The company's product, TIBSOVO? (ivosidenib) is for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase (IDH) 1 mutation. The company's other product is IDHIFA? (enasidenib) for patients with R/R AML and an IDH2 mutation. The company's pre-commercial clinical cancer product candidates include: vorasidenib, a brain-penetrant pan-IDH mutant inhibitor; and AG-270, an orally available selective inhibitor of methionine adenosyltransferase 2a.
  • TickerAGIO
  • ISINUS00847X1046
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge pattern. This pattern results in a breakdown roughly 70% of the time. Still, support at 2760 would need ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Getting Long-Term Oversold Note: We have suspended the Russell grids and Sector comments this week due to heightened volatility. Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward. Clues that a breakdown was increasingly likely started coming as early as Thursday, when the KBW Bank index broke below key $89 support we outlined last week. Friday's widening move in h...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Bullish Outlook Intact Amid rising Middle East tensions, investors have moved to safe-havens including Treasuries and gold, all while having a muted effect on the US equity market. At this point in time, the rising tensions have done virtually no damage to the bullish trends and indicators that continue to dominate the market. We remain bullish. • 10-Year Treasury. The 10-year yield has fallen to logical support at the uptrend or 1.75%, a level we expect to hold. A breakdown would raise concerns of a deeper pullback for US equities... see chart below. • Gold Testing Key Resistance. Gold...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Round Trip Back To Resistance Our base case continues to be for near-term consolidation while the market determines the implications of states' reopening (i.e., the “wait-and-see” phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Below we highlight new developments which remain generally positive. Still, many major indexes are testing logical resistance and until we see breakouts it is hard to get too bullish. · Short-Term Levels. The S&P 500 is at the upper-en...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior